Biomedical subjects
K Schad
Publications and source records attributed to K Schad.
[Intraocular pressure after taking brotizolam].
Explore the source record for details and available documents.
Noncontact detection of ocular melanoma with L-3-123I-iodo-alpha-methyltyrosine: first clinical results.
The results of the first clinical trial are presented of the newly designed tumor-seeking radiopharmaceutical L-3-123I-iodo-alpha-methyltyrosine (IMT) for noncontact detection of malignant eye melanoma by means of a nuclear medicine technique. Eye scintigraphy (ES) was performed on ten outpatients clinically suspected of harboring an intraocular melanoma. ES was carried out with a twin pinhole eye collimator attached to a high resolution gamma camera; 7-10 mCi of IMT was given intravenously to each patient 100-150 min prior to the nuclear medicine investigation. Gamma camera eye scintigraphy and the use of IMT offer a useful noninvasive alternative to the radiophosphorus uptake test. Of the ten patients, five were found not to have a melanoma either clinically or by scintigraphy, three had a melanoma by scintigraphy that was confirmed histologically, and two yielded inconclusive results.
[Are 0.1% timolol-maleate eyedrops suitable for treating chronic glaucoma? (author's transl)].
On the basis of 47 patients with chronic open-angle glaucoma, the administration of 0.1% timolol-maleate eye-drops was investigated in the form of a controlled long-term study over a period of 56 weeks. It was found that in a remarkable proportion of chronic glaucoma cases, this low concentration had an adequate, long-term effect, reducing IOP by 24-27%. The results obtained give sufficient grounds for the assumption that in the initial stages of glaucoma, the 0.1% solution is just as effective as solutions of a higher concentration, provided that a satisfactory degree of responsiveness to timolol-maleate is present from the outset. The local and systemic side-effects are relatively slight and therefore also fewer than with higher concentrations. Since in over 50% of patients with chronic glaucoma, 0.1% timolol-maleate eye-drops reduce IOP adequately over a considerable period of time, the 0.1% solution is to be recommended at all events for the initial treatment of glaucoma patients.
[Nuclear medicine demonstration of intraocular tumors using gamma-radiating radionuclides. 1st clinical results].
A non-invasive method of detecting intraocular mass lesions is described which uses 67gallium citrate and 99m-technetium pertechnetate. It was used in 33 cases. In 73.7% of the patients with malignant melanoma of the eye there was a significant increase in the storage of the tracer. There was no difference in the results obtained with 67gallium citrate and 99m-technetium pertechnetate. Small, flat and peripheral tumors may not be detected. In some cases old intraocular hemorrhages may also lead to false-positive results. In contrast to the 32P-test the method described can be used in cases with opaque media. The radiation dose is about one-tenth of that given with the 32P-test.